Join Paul Biondi (Bristol-Myers Squibb), Suzanne Bruhn (Proclara Biosciences), Deborah Dunsire (XTuit Pharmaceuticals), William Heiden (AMAG), Ed Kaye (Sarepta), Adelene Perkins (Infinity Pharmaceuticals), Al Sandrock (Biogen), Sue Washer (AGTC), and others at the Four Seasons Boston for a two-day high-level, high-energy networking event.
BOSTON, MASSACHUSETTS, MAY 24, 2017–Leading CEOs from biotech, pharmaceutical, and healthcare investing communities will gather at Boston CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston.
The Boston CEO Conference is an off-the-record networking forum for leading executives in the life sciences, offering exclusive access to key decision makers who influence deal making and investment. Attendees gain insight from presentations and panels featuring CEOs from several of the world’s leading biopharmaceutical companies. Healthcare and finance investors also attend this world-class meeting.
FDA’s Richard Moscicki will give a keynote speech. John Maraganore (Alnylam), Robert Coughlin (MassBio), David Meek (IPSEN), and Mike Ehlers (Biogen) will speak in Fireside Chats moderated by Christoph Westphal (Longwood Fund).
The conference will commence with a remembrance for the late Henri Termeer, “Remembering a Biotech Legend: Henri Termeer” with Christoph Westphal, Rob Perez, Deborah Dunsire, Geoffrey McDonough, and Richard Moscicki.
John Maraganore, CEO of Alnylam, says, “The Boston CEO conference is an invaluable opportunity for CEOs to gather in a casual and off-the-record atmosphere and discuss the most pressing issue in the biotech space and beyond. I look forward to these conferences and fully support their mission to continue to grow Boston’s thriving biopharma community.”
Panel topics include a CEO roundtable, healthcare market outlook, diversity: moving from sound bite to implementation, ensuring transparency and drug value, cell & gene therapy, building a biotech, evolving biotech boards, Boston-Bound biotech and pharma, achieving organizational turnarounds, and many more.
The 2017 Boston CEO Lifetime Achievement Award will be presented by last year’s winner, Robert Couhglin (MassBio) and 2015 winner, John Maraganore (Alnylam) on Wednesday, May 31st at 4:20 pm. Nominees include Mary Lynne Hedley (TESARO), Jeffrey Leiden (Vertex), David Meeker (fmr Sanofi Genzyme), Rob Perez (Life Science Cares), David Scheinkein (Agios), and Christopher Viehbacher (Gurnet Point Capital).
Boston CEO is sponsored by L.E.K. Consulting, Russell Reynolds Associates, ICON plc, inVentiv Health, Leerink Partners, RSM, Prolung, Corealis Pharma, and BioPharma Executive Council.
For more information or to register for the conference, visit: https://bbbiotechconference.com/conference-details.php?id=57
ABOUT BOSTON BIOTECH CONFERENCES
The Boston Biotech Conferences (BBC) mission is to build a vibrant community of biopharma leaders, which will help to drive innovation in biotech by convening leaders across industry and academia.
The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking and corporate development within the biopharma community. These off-the-record forums bring together the past, present and future leaders in the healthcare community to network, exchange ideas and share insights into the industry’s challenges and opportunities.
Contact: Arielle Jackson, email@example.com